PD, Anemia, and Roxadustat

A systematic review and meta-analysis of eight studies (n=607) evaluated the efficacy and safety of Roxadustat in PD, finding that the drug significantly increased hemoglobin and TIBC and reduced hepcidin. Ferritin, TSAT, cholesterol and triglycerides, and diastolic blood pressure were not significantly affected.